Assessing Medication Confounders Before Determination of Brain Death/Death by Neurologic Criteria: A Primer, with Opioids as a Worked Example

Clicks: 19
ID: 332842
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #120 of 247 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 247 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PURPOSE: To provide a primer on how clinicians, particularly pharmacists, can systematically assess whether a medication may confound determination of brain death/death by neurologic criteria (BD/DNC), using pharmacokinetic and pharmacodynamic principles that can be applied to any agent with the aid of tertiary references, and using opioids as a worked example. SUMMARY: All major guidelines require exclusion of central nervous system (CNS) depressant effect before BD/DNC determination, yet none provides a general method for deciding when a given medication has cleared. Rather than cataloging every agent, this primer sets out the parameters that govern how long any drug can suppress the neurologic examination: lipophilicity and volume of distribution, elimination pathway and the effect of hepatic or renal dysfunction, active metabolites, and the context-sensitive half-life, which lengthens with the duration of an infusion and is not predicted by the elimination half-life. Special states, including obesity, hypothermia, extracorporeal support, and overdose, further prolong effect; in overdose, delayed absorption and saturable elimination can invalidate the customary five-half-life rule. Routine toxicology screens miss many relevant substances, including synthetic opioids. Opioids illustrate the framework across three common scenarios: exposure before arrival, continuous infusion, and overdose. CONCLUSION: No validated serum concentration threshold defines clearance for most CNS depressants, and the safest determination rests on structured pharmacokinetic reasoning, toxicology consultation, and institutional protocols that specify how confounders are screened for and excluded, rather than on any single number or fixed waiting period.
Reference Key
openalex_W7222913626 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Brian L. Erstad, Aarti Sarwal, Yugant Khand, J. Larsen, Farshad “Mazda” Shirazi
Are you one of these authors? Claim your profile
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag348
URL
https://doi.org/10.1093/ajhp/zxag348
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.